💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vonicog Alfa

CHEMBL2107873 Phase 4 Approved Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Vonicog alfa is a recombinant von Willebrand factor produced in Chinese hamster ovary cells that replaces or supplements endogenous VWF in patients with von Willebrand disease (VWD), restoring platelet adhesion to subendothelial collagen and stabilizing coagulation factor VIII from premature degradation. It is used for the treatment and prophylaxis of bleeding episodes in adults with severe type 3 VWD when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Its recombinant origin avoids the risk of viral transmission associated with plasma-derived VWF products.

Mechanism of Action

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Vonicog alfa is a recombinant von Willebrand factor produced in Chinese hamster ovary cells that replaces or supplements endogenous VWF in patients with von Willebrand disease (VWD), restoring platelet adhesion to subendothelial collagen and stabilizing coagulation factor VIII from premature degradation. It is used for the treatment and prophylaxis of bleeding episodes in adults with severe type 3 VWD when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Its recombinant origin avoids the risk of viral transmission associated with plasma-derived …

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Vonicog Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107873. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.